New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 15, 2014
08:56 EDTJNJJohnson & Johnson sees FY net interest expense $400M-$500M
Says early Q1 data shows continued softer utilization trends impacted by the severe winter conditions. Says data shows continued slight declines in the rates of surgical and lab procedures in the U.S., similar to what was seen over the past 12 months. Says strong Q4 utilization in orthopedic procedures softened in Q1 due to some seasonality. Says confident overall about the long-term health of the market as economic conditions continue to recover. Says Japanese yen to be a headwind in 2014, although that negative impact to gross margin will increase throughout the year. Sees FY14 net interest expense $400M-$500M, effective tax rate 19%-20%. Says guidance for 2014 anticipates that the R&D tax credit will be renewed by Congress. Says expects continued pricing pressure in 2014 across many markets, particularly in Europe; says impact of this negative pricing pressure to negatively impact pretax operating margin by approximately 50bps. Says "comfortable" with models reflecting an operational sales increase on a constant currency basis of 5%-6% for the year. Says if currency exchange rates for all of 2014 were to remain where they were as of last week, sales growth rate would decrease by nearly half a percent. Says this would result in sales for 2014 on a constant currency basis of approximately $74.9B-$75.7B. Says that if exchange rates for all of 2014 were to remain where they were as of last week, then our reported EPS excluding special items would be positively impacted by approximately 6c per share due solely to exchange rate fluctuations. Comments made on the Q1 earnings conference call.
News For JNJ From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 29, 2015
14:06 EDTJNJJ&J announces study findings of paliperidone palmitate published in JAMA
Subscribe for More Information
March 27, 2015
15:14 EDTJNJJohnson & Johnson not likely to buy Intuitive Surgical, says BofA/Merrill
Subscribe for More Information
09:59 EDTJNJJohnson & Johnson to collaborate with Google to advance surgical robots
Subscribe for More Information
06:46 EDTJNJContact lens makers, discounters battling over price setting, NY Times says
Subscribe for More Information
March 25, 2015
07:29 EDTJNJLeerink to hold booth tours
Leerink Booth Tours at AAOS 2015 will be held in Las Vegas on March 25-26.
March 24, 2015
13:24 EDTJNJContact lens manufacturers accused of price-fixing, Bloomberg says
Subscribe for More Information
07:45 EDTJNJFDA Pediatric Advisory Committee holds a meeting
The Committee discusses pediatric-focused safety reviews, as mandated by the FDA Safety and Innovation Act (FDASIA) for Eli Lilly's Cymbalta, Pfizer's Quillivant XR and Revatio, Johnson & Johnson's Risperdal, GlaxoSmithKline's Advair, HFA Altabax Ointment and Fluarix Quadrivalent, Supernus Pharmaceuticals' Oxtellar XR, Teva Pharmaceutical's Qnasl and Roche's Invirase. The Committee will also discuss the safety ongoing propriety of the humanitarian device exemption for the Medtronic Activa Dystonia Therapy and for the Liposorber LA-15 System in a meeting being held in Silver Spring, Maryland on March 24 at 8 am. Webcast Link
March 23, 2015
09:03 EDTJNJLeerink analysts hold a meeting with a conference call hookup
Subscribe for More Information
March 17, 2015
05:35 EDTJNJJohnson & Johnson to invest $10M in UK government fund to fight dementia
Subscribe for More Information
March 16, 2015
15:04 EDTJNJPharmacyclics says committee recommends unblinding after primary endpoint met
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use